RPS6

Across TCGA pan-cancer cohorts, RPS6 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RPS6 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPS6 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPS6 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where RPS6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.361	0.745	.001	23	view →
GBM	OS	Median	All	0.570	0.218	.002	8	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
UCEC	DFS	Tertile	All	0.939	0.776	.033	6	view →
LSCC	OS	Median	All	0.947	0.814	.014	6	view →
LUAD	OS	Median	II,III,IV	0.449	0.893	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RPS6–CCRCC (DFS)

Open the CCRCC breakdown →